Figure 5

SC inhibits PRRSV infection after different modes of treatment. SC was added before (pre-treatment), during (co-treatment), or after (post-treatment) PRRSV SD-YL1712 infection (MOI = 1). The pre-treatment groups were inoculated with PRRSV 8, 6, 4, or 2 h after the addition of SC. The co-treatment group was infected with PRRSV and immediately treated with 10 µM SC. In the post-treatment group, cells were infected with PRRSV first, and SC was added at 2, 4, 6, or 8 h after infection. Supernatants and cells were harvested at 24 hpi for RT-qPCR, Western blotting, and viral titre assays. A Diagram of the timeline for the treatment mode experiments. B PRRSV N expression level. C PRRSV ORF7 expression level. D Supernatant virus titre. *P < 0.05; **P < 0.01; ***P < 0.001 compared with the respective virus control.